Exagen, Inc. (XGN)
7.65
-0.27
(-3.41%)
USD |
NASDAQ |
Aug 24, 16:00
7.61
-0.04
(-0.52%)
After-Hours: 20:00
Exagen Shareholders Equity (Quarterly) : 12.22M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.22M |
| March 31, 2026 | 14.43M |
| December 31, 2025 | 17.45M |
| September 30, 2025 | 18.14M |
| June 30, 2025 | 21.03M |
| March 31, 2025 | 6.403M |
| December 31, 2024 | 9.54M |
| September 30, 2024 | 12.87M |
| June 30, 2024 | 17.58M |
| March 31, 2024 | 19.99M |
| December 31, 2023 | 22.69M |
| September 30, 2023 | 27.50M |
| June 30, 2023 | 31.90M |
| March 31, 2023 | 35.94M |
| December 31, 2022 | 42.46M |
| September 30, 2022 | 56.19M |
| June 30, 2022 | 62.82M |
| March 31, 2022 | 76.16M |
| December 31, 2021 | 84.94M |
| September 30, 2021 | 90.80M |
| June 30, 2021 | 96.38M |
| March 31, 2021 | 101.47M |
| December 31, 2020 | 41.84M |
| September 30, 2020 | 44.47M |
| June 30, 2020 | 47.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 50.54M |
| December 31, 2019 | 55.66M |
| September 30, 2019 | 58.65M |
| June 30, 2019 | -0.708M |
| March 31, 2019 | -3.083M |
| December 31, 2018 | -6.734M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | -22.18M |
| September 30, 2015 | -18.61M |
| June 30, 2015 | -15.64M |
| March 31, 2015 | -17.08M |
| December 31, 2014 | -14.06M |
| September 30, 2014 | -11.65M |
| June 30, 2014 | -7.055M |
| March 31, 2014 |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Myriad Genetics, Inc. | 303.90M |
| BioRestorative Therapies, Inc. | 3.026M |
| CareDx, Inc. | 425.60M |
| Natera, Inc. | 1.821B |
| Sera Prognostics, Inc. | 59.38M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 51.94M |
| Total Liabilities (Quarterly) | 39.72M |
| Debt to Equity Ratio | 2.264 |
| Current Ratio | 3.185 |
| Net Debt Paydown Yield | -0.75% |